- Home
- BLTE vs DYN Comparison
BLTE vs DYN Comparison
Compare BLTE & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLTE | DYN |
|---|---|---|
| Founded | 2018 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.4B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BLTE | DYN |
|---|---|---|
| Price | $169.05 | $17.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $161.57 | $39.94 |
| AVG Volume (30 Days) | 237.7K | ★ 2.2M |
| Earning Date | 03-16-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.00 | $6.36 |
| 52 Week High | $174.78 | $25.00 |
Technical Indicators
Market Signals| Indicator | BLTE | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 47.66 |
| Support Level | $156.52 | $17.28 |
| Resistance Level | $171.63 | $18.58 |
| Average True Range (ATR) | 8.88 | 0.86 |
| MACD | 0.26 | 0.13 |
| Stochastic Oscillator | 79.00 | 71.43 |
Price Performance
Historical ComparisonAbout BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.